Immunogenicity of somatic mutations in human gastrointestinal cancers - PubMed (original) (raw)
. 2015 Dec 11;350(6266):1387-90.
doi: 10.1126/science.aad1253. Epub 2015 Oct 29.
Mojgan Ahmadzadeh 1, Yong-Chen Lu 1, Alena Gros 1, Simon Turcotte 1, Paul F Robbins 1, Jared J Gartner 1, Zhili Zheng 1, Yong F Li 1, Satyajit Ray 1, John R Wunderlich 1, Robert P Somerville 1, Steven A Rosenberg 2
Affiliations
- PMID: 26516200
- PMCID: PMC7445892
- DOI: 10.1126/science.aad1253
Immunogenicity of somatic mutations in human gastrointestinal cancers
Eric Tran et al. Science. 2015.
Abstract
It is unknown whether the human immune system frequently mounts a T cell response against mutations expressed by common epithelial cancers. Using a next-generation sequencing approach combined with high-throughput immunologic screening, we demonstrated that tumor-infiltrating lymphocytes (TILs) from 9 out of 10 patients with metastatic gastrointestinal cancers contained CD4(+) and/or CD8(+) T cells that recognized one to three neo-epitopes derived from somatic mutations expressed by the patient's own tumor. There were no immunogenic epitopes shared between these patients. However, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell receptor from CD8(+) TILs that targeted the KRAS(G12D) hotspot driver mutation found in many human cancers. Thus, a high frequency of patients with common gastrointestinal cancers harbor immunogenic mutations that can potentially be exploited for the development of highly personalized immunotherapies.
Copyright © 2015, American Association for the Advancement of Science.
Figures
Fig. 1.. Identification of personalized mutation-specific T cells in a patient with metastatic colon cancer (4007).
(A) Twenty-three different TIL cultures were cocultured with autologous DCs transfected with an irrelevant TMG RNA, or the indicated TMG construct encoding the various putative mutations identified with whole-exomic sequencing. T cell responses were measured the next day by means of IFN-γ ELISPOT assay (top) and flow cytometric analysis for 4-1BB up-regulation on CD8+ T cells (bottom). (B) TIL cultures 8, 16, and 23 were cocultured with DCs transfected with an irrelevant TMG RNA, or TMG-7 or TMG-14 RNA, and CD8+ T cells that up-regulated 4-1BB were purified by means of FACS and expanded. (C) IFN-γ ELISPOT assay (left axis) and flow cytometric analysis of 4-1BB expression (right axis) on TMG-7– and TMG-14–reactive CD8+ T cells isolated in (B) after an overnight coculture with DCs pulsed with long peptides encoded by either TMG-7 or TMG-14, or transfected with TMG-7 or TMG-14 RNA. (D) Autologous open-repertoire peripheral blood T cells were genetically modified with the TCRs derived from the SKIV2L and H3F3B mutation-reactive T cells identified in (B) and (C) and then cocultured with DCs pulsed with the indicated wild-type (wt) and mutated (mut) long peptides. Flow cytometric analysis is gated on live CD8+ T cells, and TCR transduction efficiencies ranged between 60 and 80%. Plate-bound antibody to CD3 (OKT3) was used as a positive control in all coculture assays. “>” ELISPOT assay is not accurate above ~500 spots. Data from (B) to (D) are representative of at least two independent experiments.
Fig. 2.. Identification of KRASG12D-mutation-specific T cells in a patient with colorectal cancer (3995).
(A) IFN-γ ELISPOT assay of P3W5+6 TILs cocultured overnight with DCs transfected with irrelevant (Irrel.) TMG or TMG-3 RNA (which encodes the KRASG12D minigene), or DCs pulsed with wt or KRASG12D 24–amino acid (AA)–long peptides. Numbers are spots per 3 × 104 TILs. (B) P3W5+6 TILs were stimulated with DCs pulsed with wt or KRASG12D 24-AA-long peptides, and 4-1BB+ CD8+ T cells were purified by means of FACS and expanded. (C) IFN-γ ELISPOT assay and flow cytometric analysis of 4-1BB expression on the KRASG12D-enriched CD8+ T cells from (B) cocultured overnight with DCs pulsed with wt or KRASG12D 24-AA-long peptides, or DCs transfected with full-length wt or KRASG12D RNA. (D) IFN-γ enzyme-linked immunosorbent assay (ELISA) of T cells genetically modified with the KRASG12D-reactive TCR cocultured with COS-7 cells cotransfected with nothing (Mock) or the indicated KRAS gene along with nothing (No HLA), or the HLA-B and -C alleles expressed by the patient. (E) IFN-γ ELISA of T cells genetically modified with the KRASG12D-reactive TCR cocultured with various pancreatic cancer cell lines transduced with nothing (Mock) or the HLA-C*08:02 allele. The presence or absence of endogenously expressed KRASG12D is shown. AS, ASPC-1; MD, MDA-Panc48; PK, PK-45p; FA, FA6-2; HP, HPAC; Bx, BxPC-3 (KRAS-wt); A8, A818.8 (KRASG12R); SK, SK-PC3 (KRASG12V); MI, MIA PaCa-2 (KRASG12C). (F) KRASG12D-reactive TILs enriched from (B) were cocultured for 6 hours with pancreatic cancer cell lines transduced with nothing (Mock) or the HLA-C*08:02 allele, and flow cytometry was used to assess CD107a expression and TNF production by means of intracellular cytokine staining. Autologous APCs (peripheral blood mononuclear cells) pulsed overnight with wt or KRASG12D 24-AA-long peptides were used as control target cells. Data are gated on CD8+ T cells expressing the KRASG12D-reactive TCR Vβ5.2. “>” ELISPOT assay is not accurate above ~500 spots. Error bars are ±SD. All data are representative of at least two independent experiments.
Similar articles
- Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J. Abrams SI, et al. Cell Immunol. 1997 Dec 15;182(2):137-51. doi: 10.1006/cimm.1997.1224. Cell Immunol. 1997. PMID: 9514698 Clinical Trial. - Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.
Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA. Turcotte S, et al. Clin Cancer Res. 2014 Jan 15;20(2):331-43. doi: 10.1158/1078-0432.CCR-13-1736. Epub 2013 Nov 11. Clin Cancer Res. 2014. PMID: 24218514 Free PMC article. - High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW, Lu J, Spencer M, Hopkins F, Tran E, Rosenberg SA, Long EO, Sun PD. Sim MJW, et al. Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12826-12835. doi: 10.1073/pnas.1921964117. Epub 2020 May 27. Proc Natl Acad Sci U S A. 2020. PMID: 32461371 Free PMC article. - Mutant ras epitopes as targets for cancer vaccines.
Abrams SI, Hand PH, Tsang KY, Schlom J. Abrams SI, et al. Semin Oncol. 1996 Feb;23(1):118-34. Semin Oncol. 1996. PMID: 8607022 Review. - Personalized vaccines for cancer immunotherapy.
Sahin U, Türeci Ö. Sahin U, et al. Science. 2018 Mar 23;359(6382):1355-1360. doi: 10.1126/science.aar7112. Science. 2018. PMID: 29567706 Review.
Cited by
- Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes.
Tokita S, Fusagawa M, Matsumoto S, Mariya T, Umemoto M, Hirohashi Y, Hata F, Saito T, Kanaseki T, Torigoe T. Tokita S, et al. Sci Adv. 2024 Sep 20;10(38):eado6491. doi: 10.1126/sciadv.ado6491. Epub 2024 Sep 18. Sci Adv. 2024. PMID: 39292790 Free PMC article. - Recent clinical researches and technological development in TIL therapy.
Matsueda S, Chen L, Li H, Yao H, Yu F. Matsueda S, et al. Cancer Immunol Immunother. 2024 Sep 12;73(11):232. doi: 10.1007/s00262-024-03793-4. Cancer Immunol Immunother. 2024. PMID: 39264449 Free PMC article. Review. - MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.
Eguren-Santamaria I, Fernández de Piérola E, Camps G, Martín-Muñoz P, Campos M, Cuculescu D, Aguilera-Buenosvinos I, Rodríguez López I, Salido-Vallejo R, Alexandru R, De Andrea CE, Álvarez-Gigli L, Berraondo P, Melero I, Sanmamed MF. Eguren-Santamaria I, et al. J Immunother Cancer. 2024 Sep 6;12(9):e008516. doi: 10.1136/jitc-2023-008516. J Immunother Cancer. 2024. PMID: 39244214 Free PMC article. - Influenza vaccination stimulates maturation of the human T follicular helper cell response.
Schattgen SA, Turner JS, Ghonim MA, Crawford JC, Schmitz AJ, Kim H, Zhou JQ, Awad W, Mettelman RC, Kim W, McIntire KM, Haile A, Klebert MK, Suessen T, Middleton WD, Teefey SA, Presti RM, Ellebedy AH, Thomas PG. Schattgen SA, et al. Nat Immunol. 2024 Sep;25(9):1742-1753. doi: 10.1038/s41590-024-01926-6. Epub 2024 Aug 20. Nat Immunol. 2024. PMID: 39164477 Free PMC article. - T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.
Anderson GSF, Chapman MA. Anderson GSF, et al. Mol Ther. 2024 Sep 4;32(9):2856-2891. doi: 10.1016/j.ymthe.2024.07.028. Epub 2024 Aug 5. Mol Ther. 2024. PMID: 39095991 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous